Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
預測未來：分析師對Ultragenyx製藥的11項預測
Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
在過去三個月中，有11位分析師提供了Ultragenyx Pharmaceutical（納斯達克股票代碼：RARE）的評級，顯示了看漲和看跌的觀點。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表彙總了他們最近的評級，闡明瞭過去30天內情緒的變化，並將其與前幾個月進行了比較。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $82.55, along with a high estimate of $114.00 and a low estimate of $48.00. This upward trend is evident, with the current average reflecting a 6.93% increase from the previous average price target of $77.20.
分析師提供了更深入的見解，確定了12個月的目標股價，平均目標價爲82.55美元，最高估計爲114.00美元，低估值爲48.00美元。這種上升趨勢顯而易見，當前的平均價格較之前的平均目標價77.20美元上漲了6.93％。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級：仔細觀察
The standing of...
通過對...
登入免費觀看全文
登入/註冊